| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PHAR.1507 |
| P698 | PubMed publication ID | 25382096 |
| P2093 | author name string | Jennifer M Trujillo | |
| Wesley Nuffer | |||
| P2860 | cites work | A role for glucagon-like peptide-1 in the central regulation of feeding | Q24314317 |
| Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study | Q28293505 | ||
| Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). | Q33960291 | ||
| Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. | Q34259412 | ||
| Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). | Q34661985 | ||
| Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 | ||
| Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function | Q35060123 | ||
| Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) | Q35976515 | ||
| Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). | Q36303786 | ||
| Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus | Q36972371 | ||
| Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). | Q37106467 | ||
| Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L) | Q37106537 | ||
| Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). | Q37106572 | ||
| Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). | Q37193446 | ||
| Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes | Q37193600 | ||
| GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus | Q38040314 | ||
| Exenatide as a novel weight loss modality in patients without diabetes | Q38063371 | ||
| Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs | Q38065817 | ||
| Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes | Q38129805 | ||
| Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study | Q38449189 | ||
| Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes | Q42169660 | ||
| Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial | Q42671884 | ||
| Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes | Q44460021 | ||
| One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. | Q44865459 | ||
| Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). | Q48273566 | ||
| Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). | Q51032432 | ||
| The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates. | Q51155265 | ||
| Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. | Q51318574 | ||
| HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. | Q51321425 | ||
| Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. | Q51321430 | ||
| Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). | Q51332907 | ||
| Liraglutide as additional treatment for type 1 diabetes. | Q51372390 | ||
| A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. | Q51381372 | ||
| Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. | Q51743679 | ||
| Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Q57412648 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 1174-1186 | |
| P577 | publication date | 2014-11-01 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents | |
| P478 | volume | 34 |
| Q26746220 | Advances in the treatment of type 2 diabetes: impact of dulaglutide |
| Q33821526 | Autophagy and its link to type II diabetes mellitus |
| Q57179222 | Battle of GLP-1 delivery technologies |
| Q90229030 | Comparison of Usability, Accuracy, Preference, and Satisfaction Among Three Once-Weekly GLP-1 Receptor Agonist Pen Devices |
| Q40113914 | Dulaglutide (LY-2189265) for the treatment of type 2 diabetes |
| Q51046610 | Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice. |
| Q89819706 | Exploring G Protein-Coupled Receptor Signaling in Primary Pancreatic Islets |
| Q36309740 | Factors influencing the longevity and replacement frequency of Provox voice prostheses |
| Q38602769 | GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice |
| Q37737463 | Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom |
| Q28067465 | Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes |
| Q37737456 | Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study |
| Q102220349 | Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence |
| Q55316993 | Insulin Sensitivity and Glucose Homeostasis Can Be Influenced by Metabolic Acid Load. |
| Q59137107 | Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study |
| Q26798049 | Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure |
| Q52721601 | Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism. |
| Q55001495 | Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes. |
| Q89940067 | Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current Advances and Future Directions |
| Q92565506 | Novel GLP-1 Analog Supaglutide Stimulates Insulin Secretion in Mouse and Human Islet Beta-Cells and Improves Glucose Homeostasis in Diabetic Mice |
| Q38299362 | Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide. |
| Q50279509 | Postprandial hyperglycemia was ameliorated by taking metformin 30 min before a meal than taking metformin with a meal; a randomized, open-label, crossover pilot study |
| Q35048157 | Resource use and outcomes associated with initiation of injectable therapies for patients with type 2 diabetes mellitus |
| Q30248510 | Role of glucagon-like peptide 1 receptor agonists in management of obesity |
| Q35654002 | Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. |
| Q64965104 | Single-Cell Heterogeneity Analysis and CRISPR Screen Identify Key β-Cell-Specific Disease Genes. |
| Q39353555 | The EP3 Receptor/Gz Signaling Axis as a Therapeutic Target for Diabetes and Cardiovascular Disease |
| Q64964485 | The Glp-1 Analog Liraglutide Protects Against Angiotensin II and Pressure Overload-Induced Cardiac Hypertrophy via PI3K/Akt1 and AMPKa Signaling. |
| Q39140294 | The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy |
| Q47109213 | Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. |
| Q52662396 | Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study. |
Search more.